Hypnotic-Sedating Drugs in the Treatment of Insomnia: Objective or Subjective Improvement?

Ortega-Albás JJ* and Gomis Devesa AJ

Clinical Neurophysiology, Department at Hospital General Universitario de Castellón, Spain

*Corresponding author: Ortega Albás JJ, Clinical Neurophysiology, Department at Hospital General Universitario de Castellón, 12004, Spain, Tel: 34-967-726-606; Email: jjorral@cono.com

Rec date: Feb 25, 2014, Acc date: March 23, 2014, Pub date: March 25, 2014

Copyright: © 2014, Ortega-Albás JJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Chronic insomnia affects a significant proportion of adult population. More precisely, around 10% of the population admits their insomnia as chronic [1]. In a recent study by the National Sleep Foundation [2], 48% of Americans referred insomnia symptoms every night, with women presenting this in a higher proportion. Insomnia is responsible for a lowering of the quality of life compared to that appearing in other chronic diseases such as diabetes, arthritis or cardiopathies [3] which usually implies treatment with hypnotic-sedative drugs in most cases [4].

Sleep Regulation Mechanisms

Sleep regulation is controlled by two independent mechanisms: the homeostatic [5] and the circadian [6]; sleep predisposition is determined both by these two mechanisms joint action and by the subject’s external condition. The homeostatic mechanism regulates the physiological need for sleep, which gradually increases with vigil, sleep deprivation and, consequently, with the accumulated sleep debt. We know the importance of the ventroposterolateral nucleus of the hypothalamus (VPLO) and its GABAergic efferent inhibitory projectionstowards the monoaminergic centers of arousal, found in the posterior hypothalamus and the medulla oblongata (tubermammillary nucleus, locus coeruleus and dorsal raphe [7]), as the basic control system of the sleep homeostatic mechanism. The significant reduction of up to 50% in the number of neurons present in the VPLO in long-living individuals, would partly explain the difficulty that this population shows to start and maintain sleep [8].

The circadian mechanism depends on an endogenous clock localized in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus, and it is capable of precisely regulating the daily transitions between sleep and vigil. Melatonin is the hormone that regulates this circadian clock with an increase in secretion towards the latter hours of the evening, as a means of promoting physiologic sleep [9].

Hypnotic-sedating Drugs Effects

Hypnotic-sedating drugs present with a subjective feeling of rest and repairing sleep the following day. However, current trends when prescribing drugs to treat insomniak look mainlyto improve the quality of sleep.

Benzodiazepines

The effect of hypnotic-sedating has been extensively studied since, when at the end of the 50s of the last century, benzodiazepines and their agonist effect on the GABA-A receptor were discovered. More specifically, the α-1 subtype of the GABA-A receptor represents 60% of all subtypes, being the most abundant in the cerebral cortex. It is on this that benzodiazepines exert their sedating, amnesic and anticonvulsant effects [11]. The hypnotic effect, the reduction in slow waves in the NREM phases, the reduction in sleep fragmentation and the decrease in duration of REM cycles-events occurring after the administration of diazepam-have been proven to be due to the action of the drug on GABA-A receptor subtypes different from-1 [12]. This suggests a predominant role of subcortical neuronal synapses. Benzodiazepines, in general, reduce the percentage of N1 and N3 phases of REM sleep (although the number of sleep cycles increase) and they increase the N2 phase of sleep. They also increment the time of latency between the spindles and the REM phase.

We can thus conclude that they increase the total NREM sleep time at the expense of phase 2, decreasing the total time of N3 and REM. Hence benzodiazepines promote a sleep which is more superficial than the one in biological conditions. Notwithstanding this, patients that are treated with the hypnotic-sedating drugs present with a subjective feeling of rest and repairing sleep the following day.

Z-group drugs

By contrast, the so-called non-benzodiazepinic hypnotics, the drugs of the Z-group (zolpidem, zaleploneandzopiclone), show a higher specificity for the GABA-A α-1 receptor subtype compared to the group of classic benzodiazepines [13]. The advantage of the Z-group drugs with respect to benzodiazepines is that they show less adverse effects, mainly the behavioral problems and the next-day somnolence. The washout period is also shorter, although the hypnotic effect is shorter as well.

Conclusion

Established the action of hypnotic-sedating on the GABA-A receptors, we believe this cannot be the only mechanism responsible for the subjective feeling of improvement of sleep, and there must be other mechanisms in relation to efficacy and tolerability/safety to the drugs. Probably these mechanisms are related not only to composition and heterogeneity of the distinct subtypes of GABA-A receptors, but also to their regional and cellular distribution, as well as to the
subcortical interactions that must regulate, at the least, the hypothalamic control of sleep-vigil cycles.

Moreover, the improvement in organization of sleep manifested by a decrease in its fragmentation and a fewer number of micro awakenings in the patients treated with benzodiazepines or hypnotic non-benzodiazepinic group-Z drugs, seems to contribute to this subjective improvement despite a superficialization of the total time of sleep. Studies on the different subtypes of GABA-A receptors apart from the majoritarian α-1 in relation to the hypothalamic-subcortical interaction occurring globally during insomnia, might open new paths of research for the development of more selective drugs which will induce a more efficient, deep and repairing sleep, with less adverse effects.

References

1. Mendelson WB, Roth T, Casella J, Roehrs T, Walsh JK, et al. (2004) The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 8: 7-17.

2. Radek KS (2013) Insomnia symptom presentation and sleep aids. J Sleep Disorders Ther 2: e122.

3. Katz DA, McHorney CA (2002) The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 51: 229-235.

4. Ashish Kumar U, Palatty PL (2013) Comparative action of sedative-hypnotics on neurophysiology of sleep. J Sleep Disorders Ther 2: 150.

5. Achermann P, Boberly AA (2003) Mathematical models of sleep regulation. Front Biosci 8: 683-693.

6. Baker FC, Angara C, Szymusiak R, McGinty D (2005) Persistence of sleep-temperature coupling after suprachiasmatic nuclei lesions in rats. Am J Physiol Regul Integr Comp Physiol 289: 827-838.

7. Saper CB, Chou TC, Scammell TE (2001) The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24: 726-731.

8. Gaus SE, Strecker RE, Tate BA, Parker RA, Saper CB (2002) Ventrolateralpreoptic nucleus contains sleep-active, galaninergic neurons in multiple mammalian species. Neuroscience 115: 285-294.

9. Mahowald MW, Schenck CH (2005) Insights from studying human sleep disorders. Nature 437: 1279-1285.

10. Chou TC, Bjorkum AA, Gaus SE, Lu J, Scammell TE, et al. (2002) Afferents to the ventrolateralpreoptic nucleus. J Neurosci 22: 977-990.

11. Möhler H, Fritschy JM, Rudolph U (2002) A new benzodiazepine pharmacology. J PharmacolExpTher 300: 2-8.

12. Tobler I, Kopp C, Deboer T, Rudolph U (2001) Diazepam-induced changes in sleep: role of the α1-1 GABA A receptor subtype. ProcNatlAcadSci U S A 98: 6464-6469.

13. Sanna E, Busonero F, Talani G, Carta M, Massa F, et al. (2002) Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA (A) receptor subtypes. Eur J Pharmacol 451: 103-110.